ClinicalTrials.gg
CompletedNCT07946198Updated Nov 18, 2026

Effect of Increased Dialysis Versus Hemofiltration

An interventional study of Increased Dialysate Flow and Increased Hemofiltration Flow in Acute Kidney Injuries and Regional Citrate Anticoagulation (RCA), sponsored by Brugmann University Hospital. Completed at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Brugmann University Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled May 2024, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 45 studies in Acute Kidney Injury with a site in Belgium — 5 open to participants now, 8 under way, none of them phase 3. Acute Kidney Injury · Belgium.

Enrollment
19th of 31
42 · median 100
Started
2024
with 3 others
No phase
15 of 45
none open now
Registered
45th of 45
by date

Among the 45 studies in Acute Kidney Injury with a site in Belgium, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 45th registered.

Acute Kidney Injury

1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

5 of the 45 studies in Acute Kidney Injury with a site in Belgium are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Acute Kidney Injury with a site in Belgium, or all of them as a file.
02

Study summary

Regional citrate anticoagulation is commonly used during continuous kidney replacement therapy (CKRT) in critically ill patients. Citrate prevents clotting in the extracorporeal circuit by reducing ionized calcium concentrations. However, adequate anticoagulation is not always achieved, and the influence of dialysis and hemofiltration on citrate removal and post-filter ionized calcium remains incompletely understood.

This prospective, single-center, interventional study compares two strategies for increasing extracorporeal clearance in critically ill patients receiving CKRT with regional citrate anticoagulation.

Patients with post-filter ionized calcium concentrations above 0.35 mmol/L two hours after treatment initiation are randomized to either an increase in dialysate flow of 1,000 mL/h or an increase in hemofiltration flow of 1,000 mL/h.

The study evaluates the effects of these two interventions on citrate clearance and post-filter ionized calcium concentrations, with the aim of improving understanding of citrate handling during CKRT.

Read the detailed description

Regional citrate anticoagulation (RCA) is used during continuous kidney replacement therapy (CKRT) to prevent clotting within the extracorporeal circuit. Its anticoagulant effect depends on the chelation of ionized calcium by citrate. Citrate removal through the extracorporeal circuit may influence both citrate exposure and post-filter ionized calcium concentrations.

The relative effects of increasing dialysate flow and increasing hemofiltration flow on citrate clearance remain insufficiently characterized.

This prospective, single-center, randomized physiological study is conducted in the intensive care unit of Brugmann University Hospital, Brussels, Belgium.

Patients receiving CKRT with RCA undergo an initial two-hour treatment period. Patients whose post-filter ionized calcium concentration remains above 0.35 mmol/L at H2 are eligible for randomization between two treatment adjustments:

  1. Dialysis strategy: increase dialysate flow by 1,000 mL/h.
  2. Hemofiltration strategy: increase hemofiltration flow by 1,000 mL/h.

Physiological and biochemical measurements are obtained to assess citrate handling and post-filter ionized calcium before and after the treatment adjustment, including measurements at H2 and H4.

The study is designed to compare the physiological effects of the two strategies and to provide evidence for optimizing regional citrate anticoagulation during CKRT.

03

Conditions studied

  • Acute Kidney Injuries
  • Regional Citrate Anticoagulation (RCA)

Browse trials for

Keywords

  • Kidney Replacement Therapy
  • citrate clearance
  • Post-Filter Ionized Calcium
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Critically ill patients with acute kidney injury requiring continuous kidney replacement therapy with regional citrate anticoagulation.

Exclusion criteria

Exclusion Criteria:

  • Prior administration of continuous kidney replacement therapy with regional citrate anticoagulation within the preceding 24 hours.
  • Blood or plasma transfusion within 24 hours before the study.
  • Severe liver failure.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Increased Dialysate Flow (HD)

    Patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L at H2 are randomized to an increase in dialysate flow of 1,000 mL/h. Citrate clearance and post-filter ionized calcium are assessed before and after the intervention, including at H4.

    Procedure: Increased Dialysate Flow

  • Experimental
    Increased Hemofiltration Flow (HF)

    Patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L at H2 are randomized to an increase in hemofiltration flow of 1,000 mL/h. Citrate clearance and post-filter ionized calcium are assessed before and after the intervention, including at H4.

    Procedure: Increased Hemofiltration Flow

Interventions

  • ProcedureIncreased Dialysate Flow

    Increase in dialysate flow rate by 1,000 mL/h at H2 in patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L.

  • ProcedureIncreased Hemofiltration Flow

    Increase in hemofiltration flow rate by 1,000 mL/h at H2 in patients receiving continuous kidney replacement therapy with regional citrate anticoagulation and presenting a post-filter ionized calcium concentration above 0.35 mmol/L.

06

What researchers measure

Primary outcomes

  1. Decrease in Ionized Calcium Across the Hemofilter

    Decrease in ionized calcium concentration across the extracorporeal hemofilter, expressed in mmol/L, assessed two hours after the start of continuous kidney replacement therapy (H2, before randomization) and two hours after the assigned treatment adjustment (H4).

    Time frame: Two hours after the start of continuous kidney replacement therapy (H2) and two hours after the assigned treatment adjustment (H4)

Secondary outcomes

  1. Achievement of Target Post-Filter Ionized Calcium

    Proportion of patients achieving a post-filter ionized calcium concentration of 0.35 mmol/L or lower, assessed at H2 (two hours after the start of continuous kidney replacement therapy).

    Time frame: Two hours after the start of continuous kidney replacement therapy (H2)

  2. Achievement of Target Post-Filter Ionized Calcium

    Proportion of patients achieving a post-filter ionized calcium concentration of 0.35 mmol/L or lower, assessed at H4 (two hours after the assigned treatment adjustment).

    Time frame: Two hours after the assigned treatment adjustment (H4)

  3. Change in Systemic Ionized Calcium Concentration

    Change in systemic ionized calcium concentration (mmol/L) between H2 (two hours after the start of continuous kidney replacement therapy) and H4 (two hours after the assigned treatment adjustment) during continuous kidney replacement therapy with regional citrate anticoagulation.

    Time frame: Two hours after the start of continuous kidney replacement therapy (H2) and two hours after the assigned treatment adjustment (H4)

Other outcomes

  1. Change in Extracorporeal Citrate Clearance

    Change in extracorporeal citrate clearance between H2 (two hours after the start of continuous kidney replacement therapy) and H4 (two hours after the assigned treatment adjustment) following an increase in dialysate flow or hemofiltration flow by 1,000 mL/h. Citrate clearance is calculated using citrate concentrations and extracorporeal circuit flow parameters.

    Time frame: Two hours after the start of continuous kidney replacement therapy (H2) and two hours after the assigned treatment adjustment (H4)

07

Study locations

2 sites
  • CHU Brugmann - Site Horta
    Brussels, Brussels Capital 1020, Belgium
  • CHU Brugmann : Site Brien
    Brussels, Brussels Capital 1030, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Sep 2025, 16 months.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 16 months is below that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
May 10, 2024
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946198
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
May 10, 2024
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Last update
Nov 18, 2026

Study contacts

Sebastien Redant, MD
principal investigator · Brugmann University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion